Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolomics and lipidomics have emerged as tools in understanding the connections of metabolic syndrome (MetS) with cardiovascular diseases (CVD), type 1 and type 2 diabetes (T1D, T2D), and metabolic dysfunction-associated steatotic liver disease (MASLD). This review highlights the applications of...

Full description

Saved in:
Bibliographic Details
Published inPhysiological research Vol. 73; no. Suppl 1; pp. S165 - S183
Main Authors Rakusanova, Stanislava, Cajka, Tomas
Format Journal Article
LanguageEnglish
Published Praha Institute of Physiology 30.08.2024
Institute of Physiology of the Czech Academy of Sciences
Subjects
Anticoagulants
Biomarkers
Cardiovascular diseases
Chromatography
Cohort analysis
Data processing
Diabetes
Diabetes mellitus (insulin dependent)
Diabetes mellitus (non-insulin dependent)
Insulin resistance
Lipids
Liver diseases
Metabolic syndrome
Metabolites
Metabolomics
Methods
Quality control
Review
Risk factors
Sample size
Solvents
Statistical power
Online AccessGet full text

Cover

More Information
Summary:Metabolomics and lipidomics have emerged as tools in understanding the connections of metabolic syndrome (MetS) with cardiovascular diseases (CVD), type 1 and type 2 diabetes (T1D, T2D), and metabolic dysfunction-associated steatotic liver disease (MASLD). This review highlights the applications of these omics approaches in large-scale cohort studies, emphasizing their role in biomarker discovery and disease prediction. Integrating metabolomics and lipidomics has significantly advanced our understanding of MetS pathology by identifying unique metabolic signatures associated with disease progression. However, challenges such as standardizing analytical workflows, data interpretation, and biomarker validation remain critical for translating research findings into clinical practice. Future research should focus on optimizing these methodologies to enhance their clinical utility and address the global burden of MetS-related diseases.
ISSN:0862-8408
1802-9973
DOI:10.33549/physiolres.935443